<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262479</url>
  </required_header>
  <id_info>
    <org_study_id>GADinLADA</org_study_id>
    <secondary_id>2019-002692-34</secondary_id>
    <nct_id>NCT04262479</nct_id>
  </id_info>
  <brief_title>Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes</brief_title>
  <acronym>GADinLADA</acronym>
  <official_title>A Pilot Study on Safety, Feasibility and Insulin-promotion by Intra-inguinal Lymph Node Injections of Glutamic Acid Decarboxylase (GAD) in Patients With LADA Type of Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamyd Medical AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of 3 intra-nodal injections of GAD-alum (Diamyd),&#xD;
      together with oral vitamin D supplementation. Safety and feasibility of the treatment will be&#xD;
      evaluated and also effects on the immune system and on the preservation of endogenous insulin&#xD;
      production.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>injection site skin reactions</measure>
    <time_frame>1 hour</time_frame>
    <description>skin reactions 1 hour post injection vs. before injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)</measure>
    <time_frame>summarized at 5 months</time_frame>
    <description>continuously monitored and registered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)</measure>
    <time_frame>summarized at 12 months</time_frame>
    <description>continuously monitored and registered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65A titer in serum</measure>
    <time_frame>at 5 months</time_frame>
    <description>concentration in serum after the first injection vs baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65A titer in serum</measure>
    <time_frame>at 12 months</time_frame>
    <description>concentration in serum after the first injection vs baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>5 months after first injection</time_frame>
    <description>measured by glucagon- and MMTT stimulated C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>12 months after first injection</time_frame>
    <description>measured by glucagon- and MMTT stimulated C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>from baseline to 5 and 12 months after the first injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>from baseline to 5 and 12 months after the first injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting C-peptide</measure>
    <time_frame>between baseline and 5 and 12 months after the first injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum C-peptide during Mixed Meal Tolerance Test (MMTT)</measure>
    <time_frame>between baseline and 5 and 12 months after the first injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Latent Autoimmune Diabetes in Adults</condition>
  <arm_group>
    <arm_group_label>GAD-vaccination with vitamin D suppletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart.&#xD;
Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel</intervention_name>
    <description>3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden</description>
    <arm_group_label>GAD-vaccination with vitamin D suppletion</arm_group_label>
    <other_name>GAD-alum (Diamyd(R))</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden</description>
    <arm_group_label>GAD-vaccination with vitamin D suppletion</arm_group_label>
    <other_name>Divisun 2000 IE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent by the patient.&#xD;
&#xD;
          2. Diagnosis of LADA and diabetes debut within the last 18 months before inclusion. LADA&#xD;
             should be defined by the criteria of age ≥30 years at the onset of diabetes, anti-GAD&#xD;
             positivity and no clinical need for permanent insulin treatment during the first 3&#xD;
             months after the diagnosis of diabetes.&#xD;
&#xD;
          3. Fasting C-peptid levels ≥ 0.3 nmol/l&#xD;
&#xD;
          4. High GADA titers (&gt;190 U/ml)&#xD;
&#xD;
          5. Patients must be insulin independent at baseline by clinical judgement and C-peptide&#xD;
             criteria&#xD;
&#xD;
          6. Antidiabetic medication in the form of metformin is acceptable for inclusion as well&#xD;
             as medications not mentioned under exclusion criteria&#xD;
&#xD;
          7. Females must agree to avoid pregnancy, and must have a negative urine pregnancy test.&#xD;
&#xD;
        Patients of childbearing potential must agree to use adequate contraception, until one (1)&#xD;
        year after the last administration of GAD-alum. Adequate contraception is as follows:&#xD;
&#xD;
        For females of childbearing potential:&#xD;
&#xD;
          1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or&#xD;
             implanted hormonal contraceptives&#xD;
&#xD;
          2. combined (estrogen and progestogen containing)&#xD;
&#xD;
          3. oral, intravaginal or transdermal progesterone hormonal contraception associated with&#xD;
             inhibition of ovulation&#xD;
&#xD;
          4. intrauterine device&#xD;
&#xD;
          5. intrauterine hormone-releasing system (for example, progestin-releasing coil)&#xD;
&#xD;
          6. bilateral tubal occlusion&#xD;
&#xD;
          7. vasectomized male (with appropriate post vasectomy documentation of the absence of&#xD;
             sperm in the ejaculate)&#xD;
&#xD;
          8. male partner using condom&#xD;
&#xD;
          9. abstinence from heterosexual intercourse&#xD;
&#xD;
        For males of childbearing potential:&#xD;
&#xD;
          1. condom (male)&#xD;
&#xD;
          2. abstinence from heterosexual intercourse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or previous treatment with immunosuppressant therapy (topical or inhaled&#xD;
             steroids are accepted)&#xD;
&#xD;
          2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of&#xD;
             headache or in connection with fever a few days will be accepted)&#xD;
&#xD;
          3. Systemic treatment with glucocorticoids&#xD;
&#xD;
          4. Treatment with any vaccine, including influenza vaccine, within 1 month prior to&#xD;
             planned first study drug dose or planned treatment with any vaccine up to 1 month&#xD;
             after the last injection with study drug&#xD;
&#xD;
          5. Antidiabetic medication (metformin excepted)&#xD;
&#xD;
          6. Significantly abnormal hematology results at screening (i.e. anemia with hemoglobin &lt;&#xD;
             12 g/L).&#xD;
&#xD;
          7. A history of epilepsy, head trauma or cerebrovascular accident, or clinical features&#xD;
             of continuous motor unit activity in proximal muscles&#xD;
&#xD;
          8. Clinically significant history of acute reaction to vaccines in the past.&#xD;
&#xD;
          9. Renal disease (as defined by serum creatinine &gt;150 µmol/l)&#xD;
&#xD;
         10. Serious cardiovascular events (myocardial infarction, stroke) within the last year&#xD;
             preceding recruitment.&#xD;
&#xD;
         11. Participation in other clinical trials with a new chemical entity within the previous&#xD;
             3 months&#xD;
&#xD;
         12. A history of alcohol or drug abuse&#xD;
&#xD;
         13. Known HIV or hepatitis&#xD;
&#xD;
         14. Presence of associated serious disease or condition, including active skin infections&#xD;
             that preclude intralymphatic injection, which in the opinion of the investigator makes&#xD;
             the patient non-eligible for the study&#xD;
&#xD;
         15. Other serious chronic disease as judged by investigator.&#xD;
&#xD;
         16. Females who are lactating, are pregnant or intend to become pregnant.&#xD;
&#xD;
         17. Inability or unwillingness to comply with the provisions of this protocol&#xD;
&#xD;
         18. Deemed by the investigator not being able to follow instructions and/or follow the&#xD;
             study protocol&#xD;
&#xD;
         19. Treatment any other supplementation of with vitamin D, marketed or not, or unwilling&#xD;
             to abstain from such medication during the trial 120 days daily intake of Divisun&#xD;
             (non-investigational medicinal product)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Hildur Henriksen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>St Olavs Hospital, Medisinsk Klinikk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torstein Baade Rø, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology, IKOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiskt Specialistcentrum, Centrum for Diabetes, and Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, Grill V, Björklund A. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. Diabetes Obes Metab. 2019 Oct;21(10):2219-2227. doi: 10.1111/dom.13797. Epub 2019 Jun 19.</citation>
    <PMID>31148332</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glutamic Acid Decarboxylase</keyword>
  <keyword>Alum Compounds</keyword>
  <keyword>Injections</keyword>
  <keyword>Inguinal Canal</keyword>
  <keyword>Diamyd</keyword>
  <keyword>rhGAD65</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Latent Autoimmune Diabetes in Adults</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

